Single Infusion Of CRISPR/Cas9-Based Treatment Appears Safe In Patients With Hereditary Angioedema, Interim Trial Results Suggest

MedPage Today (11/15, Boyles) reports, “The future medical promise of CRISPR/Cas9 gene-editing appears to be a present-day reality for a small group of patients with the rare genetic condition known as hereditary angioedema (HAE).” Interim results “from a...